Insiders who reported open-market trades in the last 12 months at the companies Daniel T. Scavilla files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Stephen T. Zarrilli - $4.28M in GMED purchases and sales in the last 12 months
David D. Davidar - $4.17M in GMED purchases and sales in the last 12 months
Kelly Huller - $3.44M in GMED purchases and sales in the last 12 months
James R. Tobin - $2.24M in GMED purchases and sales in the last 12 months
Kyle Kline - $2.03M in GMED purchases and sales in the last 12 months
Gregory T. Lucier - $894K in XRAY purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Daniel T. Scavilla is a corporate insider, tracked as President, CEO & Member of BOD, Director of DENTSPLY SIRONA Inc. (XRAY). InsiderAlpha holds 10 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Daniel T. Scavilla last file a Form 4?
The most recent primary Form 4 on record is dated 26 May 2026, one of 10 filings going back to 2024.
Has Daniel T. Scavilla been buying or selling stock?
Recorded transactions: 0 open-market purchases and 2 open-market sales ($15.85M) across all tracked filings.
Daniel T. Scavilla is President, CEO & Member of BOD, Director of DENTSPLY SIRONA Inc. (XRAY). 10 SEC Form 4 filings on record going back to 2024, most recently on 26 May 2026. Most recent open-market trade: sold $11.05M of GMED on 25 November 2024. Lifetime open-market sales: $15.85M.
Recent transactions
12
The latest 12 SEC Form 4 transactions reported by Daniel T. Scavilla.
InsiderAlpha's records for Daniel T. Scavilla go back to 2024: 10 primary Form 4 filings, an average of 3.3 per year. 10 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
